Forward-looking Guidance

Projected “cash utilization” is equal to projected non-GAAP net loss excluding depreciation but adjusted to include changes in deferred revenue and projected capital expenditures. Projected non-GAAP net loss is equal to projected net loss applicable to common stockholders excluding (i) stock compensation expense, (ii) amortization of intangible assets and (iii) subsidiary preferred stock accretion. Cash utilization (Human Therapeutics) is cash utilization excluding Codexis and Verdia.

Return Financial Reconciliations